Mizuho reaffirmed their buy rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report released on Friday morning, AnalystRatings.com reports. Mizuho currently has a $23.00 target price on the biotechnology company’s stock.
CNCE has been the subject of a number of other research reports. BidaskClub upgraded Concert Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, May 8th. HC Wainwright restated a buy rating and issued a $26.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, May 3rd. Zacks Investment Research upgraded Concert Pharmaceuticals from a strong sell rating to a hold rating in a research note on Wednesday, May 1st. TheStreet lowered Concert Pharmaceuticals from a c- rating to a d rating in a research note on Friday, March 1st. Finally, UBS Group set a $13.00 target price on Concert Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Concert Pharmaceuticals currently has an average rating of Hold and a consensus price target of $20.00.
Shares of Concert Pharmaceuticals stock traded down $0.01 during trading on Friday, reaching $10.58. The company’s stock had a trading volume of 124,808 shares, compared to its average volume of 155,263. The company has a debt-to-equity ratio of 0.11, a current ratio of 20.44 and a quick ratio of 20.44. The stock has a market capitalization of $252.00 million, a price-to-earnings ratio of -4.41 and a beta of 0.88. Concert Pharmaceuticals has a 1-year low of $9.21 and a 1-year high of $21.00.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.31). The firm had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $16.08 million. Concert Pharmaceuticals had a negative return on equity of 41.72% and a negative net margin of 7,118.04%. On average, equities research analysts anticipate that Concert Pharmaceuticals will post -3.86 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in Concert Pharmaceuticals by 23.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 186,831 shares of the biotechnology company’s stock worth $2,773,000 after acquiring an additional 34,920 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Concert Pharmaceuticals by 8.1% during the 3rd quarter. Vanguard Group Inc now owns 1,225,849 shares of the biotechnology company’s stock valued at $18,192,000 after buying an additional 91,659 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Concert Pharmaceuticals by 2.0% during the 4th quarter. Prudential Financial Inc. now owns 81,616 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 1,610 shares during the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Concert Pharmaceuticals during the 4th quarter valued at about $48,000. Finally, First Manhattan Co. raised its stake in shares of Concert Pharmaceuticals by 85.8% during the 4th quarter. First Manhattan Co. now owns 1,049,534 shares of the biotechnology company’s stock valued at $13,171,000 after buying an additional 484,739 shares during the last quarter. Institutional investors own 71.96% of the company’s stock.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Story: How to identify percentage decliners
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.